RU2630583C2 - Аналоги цистамина, применяемые для лечения болезни паркинсона - Google Patents

Аналоги цистамина, применяемые для лечения болезни паркинсона Download PDF

Info

Publication number: RU2630583C2
Authority: RU; Russia
Prior art keywords: cystamine; disease; parkinson; pharmaceutically acceptable; patient
Prior art date: 2011-02-23

Application number

RU2013137645A

Other languages

English (en)

Russian (ru)

Other versions

RU2013137645A (ru

Inventor

Франческа СИЧЕТТИ

Клауди РУИЛЛАРД

Фредерик КАЛОН

Original Assignee

Университет Лаваль

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-23

Filing date

2012-02-23

Publication date

2017-09-11

2012-02-23 Application filed by Университет Лаваль filed Critical Университет Лаваль

2015-02-20 Publication of RU2013137645A publication Critical patent/RU2013137645A/ru

2017-09-11 Application granted granted Critical

2017-09-11 Publication of RU2630583C2 publication Critical patent/RU2630583C2/ru

Links

OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical class CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 title claims abstract description 211
208000018737 Parkinson disease Diseases 0.000 title claims abstract description 102
229940099500 cystamine Drugs 0.000 claims abstract description 121
150000003839 salts Chemical class 0.000 claims abstract description 73
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical class NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims abstract description 68
229960003151 mercaptamine Drugs 0.000 claims abstract description 60
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 56
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 56
235000018417 cysteine Nutrition 0.000 claims abstract description 56
210000002569 neuron Anatomy 0.000 claims abstract description 51
239000003795 chemical substances by application Substances 0.000 claims abstract description 33
208000024891 symptom Diseases 0.000 claims abstract description 29
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
239000003814 drug Substances 0.000 claims abstract description 12
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 42
229960003080 taurine Drugs 0.000 claims description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 11
230000004770 neurodegeneration Effects 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 6
230000037396 body weight Effects 0.000 claims description 2
210000004556 brain Anatomy 0.000 abstract description 54
230000000694 effects Effects 0.000 abstract description 15
238000010521 absorption reaction Methods 0.000 abstract description 13
239000000126 substance Substances 0.000 abstract description 11
210000005064 dopaminergic neuron Anatomy 0.000 abstract description 8
210000003050 axon Anatomy 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 83
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 68
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 61
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 59
239000011780 sodium chloride Substances 0.000 description 49
238000000034 method Methods 0.000 description 48
239000000203 mixture Substances 0.000 description 46
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 32
241001465754 Metazoa Species 0.000 description 30
150000001875 compounds Chemical class 0.000 description 30
238000002474 experimental method Methods 0.000 description 29
230000010412 perfusion Effects 0.000 description 29
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 28
238000004128 high performance liquid chromatography Methods 0.000 description 26
108020004999 messenger RNA Proteins 0.000 description 25
101150026563 NR4A2 gene Proteins 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 21
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000007924 injection Substances 0.000 description 21
238000002347 injection Methods 0.000 description 21
239000000243 solution Substances 0.000 description 19
238000011161 development Methods 0.000 description 17
230000018109 developmental process Effects 0.000 description 17
230000003902 lesion Effects 0.000 description 17
230000008499 blood brain barrier function Effects 0.000 description 16
210000001218 blood-brain barrier Anatomy 0.000 description 16
230000003291 dopaminomimetic effect Effects 0.000 description 15
210000003523 substantia nigra Anatomy 0.000 description 15
229960003638 dopamine Drugs 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
238000012360 testing method Methods 0.000 description 13
230000007423 decrease Effects 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
238000005259 measurement Methods 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
238000011065 in-situ storage Methods 0.000 description 10
239000000902 placebo Substances 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000003643 water by type Substances 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
239000005720 sucrose Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
-1 cystine disulfide derivative Chemical class 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
239000007928 intraperitoneal injection Substances 0.000 description 8
230000003287 optical effect Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000007473 univariate analysis Methods 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
208000023105 Huntington disease Diseases 0.000 description 7
229930040373 Paraformaldehyde Natural products 0.000 description 7
238000007901 in situ hybridization Methods 0.000 description 7
229920002866 paraformaldehyde Polymers 0.000 description 7
230000008569 process Effects 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
238000001262 western blot Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
150000001945 cysteines Chemical class 0.000 description 6
230000007850 degeneration Effects 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
239000011521 glass Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000037023 motor activity Effects 0.000 description 6
230000000324 neuroprotective effect Effects 0.000 description 6
230000001918 neurorescue Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000007492 two-way ANOVA Methods 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000000326 densiometry Methods 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
238000001000 micrograph Methods 0.000 description 5
238000010172 mouse model Methods 0.000 description 5
210000001577 neostriatum Anatomy 0.000 description 5
238000011002 quantification Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102000006382 Ribonucleases Human genes 0.000 description 4
108010083644 Ribonucleases Proteins 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
229960004046 apomorphine Drugs 0.000 description 4
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
239000000969 carrier Substances 0.000 description 4
150000003943 catecholamines Chemical class 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000003447 ipsilateral effect Effects 0.000 description 4
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
229960003299 ketamine Drugs 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000032258 transport Effects 0.000 description 4
230000003313 weakening effect Effects 0.000 description 4
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
229960001600 xylazine Drugs 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
241001573498 Compacta Species 0.000 description 3
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000000211 autoradiogram Methods 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
229960003067 cystine Drugs 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000001652 frontal lobe Anatomy 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000036541 health Effects 0.000 description 3
230000003862 health status Effects 0.000 description 3
VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 3
230000002055 immunohistochemical effect Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
239000004090 neuroprotective agent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000000825 ultraviolet detection Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
239000008096 xylene Substances 0.000 description 3
NSKJTUFFDRENDM-ZVGUSBNCSA-N 2-aminoethanethiol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound NCCS.OC(=O)[C@H](O)[C@@H](O)C(O)=O NSKJTUFFDRENDM-ZVGUSBNCSA-N 0.000 description 2
XROXHZMRDABMHS-UHFFFAOYSA-N 7-fluoro-2,1,3-benzoxadiazole-4-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C2=NON=C12 XROXHZMRDABMHS-UHFFFAOYSA-N 0.000 description 2
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
101150017888 Bcl2 gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
239000004201 L-cysteine Substances 0.000 description 2
235000013878 L-cysteine Nutrition 0.000 description 2
125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
206010033372 Pain and discomfort Diseases 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108020004518 RNA Probes Proteins 0.000 description 2
239000003391 RNA probe Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
238000010162 Tukey test Methods 0.000 description 2
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
239000012445 acidic reagent Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000003788 cerebral perfusion Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229940008046 cysteamine bitartrate Drugs 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000001917 fluorescence detection Methods 0.000 description 2
210000003194 forelimb Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
238000002991 immunohistochemical analysis Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000035987 intoxication Effects 0.000 description 2
231100000566 intoxication Toxicity 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000001259 mesencephalon Anatomy 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
238000010606 normalization Methods 0.000 description 2
210000002589 oculomotor nerve Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229940069575 rompun Drugs 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000002636 symptomatic treatment Methods 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
KOWJANGMTAZWDT-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin-1-ium;chloride Chemical compound Cl.C1N(C)CCC(C=2C=CC=CC=2)=C1 KOWJANGMTAZWDT-UHFFFAOYSA-N 0.000 description 1
OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical group Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
OWHRXGOUYLKIPH-UHFFFAOYSA-N 2-cyclohexa-1,5-dien-1-ylacetic acid Chemical compound OC(=O)CC1=CCCC=C1 OWHRXGOUYLKIPH-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
102000034263 Amino acid transporters Human genes 0.000 description 1
108050005273 Amino acid transporters Proteins 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
206010011777 Cystinosis Diseases 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000016252 Huntingtin Human genes 0.000 description 1
108050004784 Huntingtin Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000007873 MPTP Poisoning Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
101100405123 Mus musculus Nr4a2 gene Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
239000005844 Thymol Substances 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000002528 anti-freeze Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960004596 cabergoline Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
210000004004 carotid artery internal Anatomy 0.000 description 1
RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
235000007746 carvacrol Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
241001233037 catfish Species 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
229940043350 citral Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940028841 cystagon Drugs 0.000 description 1
229940097265 cysteamine hydrochloride Drugs 0.000 description 1
238000011157 data evaluation Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
238000005238 degreasing Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
210000004002 dopaminergic cell Anatomy 0.000 description 1
230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000007667 floating Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000010439 graphite Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000007154 intracellular accumulation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
229930007744 linalool Natural products 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004898 mitochondrial function Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000004766 neurogenesis Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000001928 neurorestorative effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
235000021395 porridge Nutrition 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
229960003089 pramipexole Drugs 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002633 protecting effect Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000000718 radiation-protective agent Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
229960001879 ropinirole Drugs 0.000 description 1
229960003179 rotigotine Drugs 0.000 description 1
KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229960000790 thymol Drugs 0.000 description 1
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
229960004603 tolcapone Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000007306 turnover Effects 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

RU2013137645A 2011-02-23 2012-02-23 Аналоги цистамина, применяемые для лечения болезни паркинсона RU2630583C2 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161445577P	2011-02-23	2011-02-23
CA2732440A CA2732440C (en)	2011-02-23	2011-02-23	Cystamine analogues for the treatment of parkinson`s disease
US61/445,577		2011-02-23
CA2,732,440		2011-02-23
PCT/CA2012/050106 WO2012113079A1 (en)	2011-02-23	2012-02-23	Cystamine analogues for the treatment of parkinson's disease

Publications (2)

Publication Number	Publication Date
RU2013137645A RU2013137645A (ru)	2015-02-20
RU2630583C2 true RU2630583C2 (ru)	2017-09-11

Family

ID=46717621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2013137645A RU2630583C2 (ru)	2011-02-23	2012-02-23	Аналоги цистамина, применяемые для лечения болезни паркинсона

Country Status (11)

Country	Link
US (1)	US20140073694A1 (2)
EP (1)	EP2678009B1 (2)
JP (1)	JP6000985B2 (2)
KR (1)	KR20140115239A (2)
CN (1)	CN103442704A (2)
AU (1)	AU2012220314B2 (2)
BR (1)	BR112013021616A2 (2)
CA (1)	CA2732440C (2)
MX (1)	MX350195B (2)
RU (1)	RU2630583C2 (2)
WO (1)	WO2012113079A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR096629A1 (es) *	2013-06-17	2016-01-20	Raptor Pharmaceuticals Inc	Métodos para analizar composiciones de cisteamina
TW201618760A (zh) *	2014-11-05	2016-06-01	雷普特製藥有限公司	使用半胱胺組合物治療亨廷頓氏病之方法
AU2016258179B2 (en) *	2015-05-06	2021-07-01	Synagile Corporation	Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
WO2017004485A1 (en)	2015-07-02	2017-01-05	Raptor Pharmaceuticals Inc.	Ado-resistant cysteamine analogs and uses thereof
CN108496330B (zh)	2016-03-30	2021-07-09	Oppo广东移动通信有限公司	中继传输的方法和装置
JP7538541B2 (ja) *	2019-03-26	2024-08-22	ザリージェンツオブザユニバーシティオブカリフォルニア	置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用
US12576051B2 (en) *	2019-07-30	2026-03-17	The Regents Of The University Of California	Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) *	2025-04-07	2025-08-15	北京大学深圳研究生院	胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) *	2025-07-09	2025-09-16	中南大学湘雅医院	胱胺在制备治疗脓毒症脑病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004069175A2 (en) *	2003-02-02	2004-08-19	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
RU2255775C1 (ru) *	2003-12-25	2005-07-10	Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук	Способ лечения болезни паркинсона
WO2008143876A2 (en) *	2007-05-14	2008-11-27	The Trustees Of Columia University In The City Of New York	Agents and assays for modulating neurodegeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3659588A1 (en) *	2006-01-27	2020-06-03	The Regents of The University of California	Enterically coated cysteamine and salts thereof
MX2010013766A (es) *	2008-06-13	2011-03-15	Teva Pharmaceutical Ind Ltd Star	Rasagilina para modificacion de enfermedad de parkinson.

2011
- 2011-02-23 CA CA2732440A patent/CA2732440C/en not_active Expired - Fee Related
2012
- 2012-02-23 EP EP12750124.5A patent/EP2678009B1/en not_active Not-in-force
- 2012-02-23 MX MX2013009608A patent/MX350195B/es active IP Right Grant
- 2012-02-23 AU AU2012220314A patent/AU2012220314B2/en not_active Ceased
- 2012-02-23 BR BR112013021616-6A patent/BR112013021616A2/pt not_active IP Right Cessation
- 2012-02-23 JP JP2013554768A patent/JP6000985B2/ja not_active Expired - Fee Related
- 2012-02-23 RU RU2013137645A patent/RU2630583C2/ru not_active IP Right Cessation
- 2012-02-23 WO PCT/CA2012/050106 patent/WO2012113079A1/en not_active Ceased
- 2012-02-23 US US14/000,234 patent/US20140073694A1/en not_active Abandoned
- 2012-02-23 KR KR1020137024680A patent/KR20140115239A/ko not_active Ceased
- 2012-02-23 CN CN2012800099995A patent/CN103442704A/zh active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004069175A2 (en) *	2003-02-02	2004-08-19	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
RU2255775C1 (ru) *	2003-12-25	2005-07-10	Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук	Способ лечения болезни паркинсона
WO2008143876A2 (en) *	2007-05-14	2008-11-27	The Trustees Of Columia University In The City Of New York	Agents and assays for modulating neurodegeneration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOUSQUET M et al. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J.Neurochem. 2010 Sep;1146):1651-8 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/20569301). GIBRAT C et al. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog.Neuropsychopharmacol.Biol.Psychiatry 2010 Feb 1; 34(1):193-203 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/19913065). STACK EC et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 2008 Mar; 1782(3): 151-62 [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/18206128) , c.159 2-я колонка 2-й абзац - с.160. *
BOUSQUET M et al. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J.Neurochem. 2010 Sep;1146):1651-8 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/20569301). GIBRAT C et al. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog.Neuropsychopharmacol.Biol.Psychiatry 2010 Feb 1; 34(1):193-203 Реферат [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/19913065). STACK EC et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 2008 Mar; 1782(3): 151-62 [он-лайн] [найдено 09.04.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/18206128) реферат, c.159 2-я колонка 2-й абзац - с.160. *
РУКОВОДСТВО ПО МЕДИЦИНЕ THE MERCK MANUAL Гл. ред. Р.Беркоу М., Мир 1997 т.1 с.1021 глава Болезнь Паркинсона 1-й абзац. *

Also Published As

Publication number	Publication date
JP2014508758A (ja)	2014-04-10
EP2678009A1 (en)	2014-01-01
AU2012220314B2 (en)	2017-04-06
KR20140115239A (ko)	2014-09-30
WO2012113079A1 (en)	2012-08-30
CA2732440C (en)	2017-10-31
RU2013137645A (ru)	2015-02-20
MX350195B (es)	2017-08-30
US20140073694A1 (en)	2014-03-13
EP2678009B1 (en)	2017-11-01
MX2013009608A (es)	2013-09-16
CA2732440A1 (en)	2012-08-23
AU2012220314A1 (en)	2013-08-22
BR112013021616A2 (pt)	2020-09-29
CN103442704A (zh)	2013-12-11
EP2678009A4 (en)	2014-08-06
JP6000985B2 (ja)	2016-10-05

Legal Events

Date	Code	Title	Description
2015-09-10	HE9A	Changing address for correspondence with an applicant
2020-01-20	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20190224

Publication	Publication Date	Title
RU2630583C2 (ru)	2017-09-11	Аналоги цистамина, применяемые для лечения болезни паркинсона
Salamon et al.	2020	Neuroprotection in Parkinson’s disease: facts and hopes: A. Salamon et al.
Wei et al.	2005	Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently
Rausch et al.	2022	From the tyrosine hydroxylase hypothesis of Parkinson’s disease to modern strategies: a short historical overview
Kidd et al.	2011	Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease
Cui et al.	2017	Vitamin D receptor activation influences NADPH oxidase (NOX2) activity and protects against neurological deficits and apoptosis in a rat model of traumatic brain injury
Miyazaki et al.	2016	Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice
Onaolapo et al.	2021	Peripheral and central glutamate dyshomeostasis in neurodegenerative disorders
Amin et al.	2020	Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period
Mahan	2012	Neuroprotective, neurotherapeutic, and neurometabolic effects of carbon monoxide
Althobaiti et al.	2016	Effects of ceftriaxone on glial glutamate transporters in Wistar rats administered sequential ethanol and methamphetamine
Esposito et al.	2007	Death in the substantia nigra: a motor tragedy
Li et al.	2024	Exosomes derived from DPA-treated UCMSCs attenuated depression-like behaviors and neuroinflammation in a model of depression induced by chronic stress
Li et al.	2024	Brain-targeted ursolic acid nanoparticles for anti-ferroptosis therapy in subarachnoid hemorrhage
Wang et al.	2019	Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
Lin et al.	2025	Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease
JP5901770B2 (ja)	2016-04-13	Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
Ching et al.	2015	A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: increasing glutamate uptake with PPARγ agonists
Gola et al.	2023	MMF induces antioxidative and anaplerotic pathways and is neuroprotective in hyperexcitability in vitro
Lavrova et al.	2021	Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products
Ikenouchi-Sugita et al.	2009	Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex
Wang et al.	2026	Role of glycolysis-mediated histone lactylation in microglial activation and progression of neurodegenerative diseases
Nishikawa et al.	2022	D-Serine: Basic Aspects with a Focus on Psychosis
Wu et al.	2026	Bufotenidine attenuates astrocyte ferroptosis in depressive-like behaviors through targeting GluA1 to reduce neuronal lipid synthesis
WO2023212795A1 (en)	2023-11-09	Use of glycine transporter- 1 antagonists as vascular dementia and/or stroke prophylactic/treatment agents